|  Help  |  About  |  Contact Us

Publication : β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway.

First Author  Bento AF Year  2011
Journal  Am J Pathol Volume  178
Issue  3 Pages  1153-66
PubMed ID  21356367 Mgi Jnum  J:169691
Mgi Id  MGI:4941665 Doi  10.1016/j.ajpath.2010.11.052
Citation  Bento AF, et al. (2011) beta-Caryophyllene Inhibits Dextran Sulfate Sodium-Induced Colitis in Mice through CB2 Receptor Activation and PPARgamma Pathway. Am J Pathol 178(3):1153-66
abstractText  Cannabinoid receptor 2 (CB2) activation is suggested to trigger the peroxisome proliferator-activated receptor-gamma (PPARgamma) pathway, and agonists of both receptors improve colitis. Recently, the plant metabolite (E)-beta-caryophyllene (BCP) was shown to bind to and activate CB2. In this study, we examined the anti-inflammatory effect of BCP in dextran sulfate sodium (DSS)-induced colitis and analyzed whether this effect was mediated by CB2 and PPARgamma. Oral treatment with BCP reduced disease activity, colonic macro- and microscopic damage, myeloperoxidase and N-acetylglucosaminidase activities, and levels and mRNA expression of colonic tumor necrosis factor-alpha, IL-1beta, interferon-gamma, and keratinocyte-derived chemokine. BCP treatment also inhibited the activation of extracellular signal-regulated kinase 1/2, nuclear factor kappaB, IkappaB-kinase alpha/beta, cAMP response element binding and the expression of caspase-3 and Ki-67. Moreover, BCP enhanced IL-4 levels and forkhead box P3 mRNA expression in the mouse colon and reduced cytokine levels (tumor necrosis factor-alpha, keratinocyte-derived chemokine, and macrophage-inflammatory protein-2) in a culture of macrophages stimulated with lipopolysaccharide. The use of the CB2 antagonist AM630 or the PPARgamma antagonist GW9662 significantly reversed the protective effect of BCP. Confirming our results, AM630 reversed the beneficial effect of BCP on pro-inflammatory cytokine expression in IEC-6 cells. These results demonstrate that the anti-inflammatory effect of BCP involves CB2 and the PPARgamma pathway and suggest BCP as a possible therapy for the treatment of inflammatory bowel disease.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

3 Bio Entities

Trail: Publication

0 Expression